


Supplemental Figures and Tables

Hepatic TRAP80 Selectively Regulates Lipogenic Activity of Liver X Receptor

Geun Hyang Kim, Gyun-Sik Oh, Jin Yoon, Gang Gu Lee, Ki-Up Lee, and Seung-Whan Kim


Supplemental Figure 1



Supplemental Figure 1. Expression and purification of the LBD of LXR α fused to GST.


(A) Schematic representation of LXR α LBD fused to GST. The carboxyl terminus (residues 159–445) of LXR α is fused to GST. (B) Overexpression and purification of GST–LXR α LBD (GST-LBD). Bacterially expressed GST-LXR α LBD was purified on glutathione-Sepharose beads and used as immobilized bait.

Supplemental Figure 2



Supplemental Figure 2. TRAP230 and CRSP130 stimulate ligand-dependent activation of the *SREBP-1c* and *ABCA1* promoter. HepG2 cells were transfected with a luciferase reporter plasmid under the control of synthetic LXRE (**A**, $n = 5$), *SREBP-1c* promoter (**B**, $n = 7$), or *ABCA1* promoter (**C**, $n = 6$). Data are presented as the mean \pm SEM. T1317, T0901317. * $P < 0.05$, ** $P < 0.01$, one-way ANOVA.


Supplemental Figure 3



Supplemental Figure 3. LXR α -specific knockdown using siRNA in primary hepatocytes.


Mouse primary hepatocytes were transfected with LXR α siRNA (sc-38829, Santa Cruz) or control siRNA (sc-37007, Santa Cruz). The transcript levels of LXR α (A) and LXR β (B) were analyzed by qRT-PCR.

Supplemental Figure 4




Supplemental Figure 4. Differential effects of TRAP80 siRNA on SREBP-1c and ABCA1 transcript levels. HepG2 cells were transfected with TRAP80 siRNA (sc-38575, Santa Cruz) or control siRNA (sc-37007, Santa Cruz) ($n = 3$) and the transcript levels of TRAP80 (**A**), SREBP-1c (**B**), and ABCA1 (**C**) in the presence or absence of T0901317 were analyzed by qRT-PCR. Data are presented as the mean \pm SEM. $*P < 0.05$, $***P < 0.001$, one-way ANOVA.

Supplemental Figure 5




Supplemental Figure 5. Delivery of Ad-shTRAP80 to the liver via tail vein injection. (A) Mice were injected with Ad-shTRAP80 (1×10^{11} particles/20 g) via the tail vein. Five days after injection, liver, lung, spleen, and kidney tissues were harvested and cryo-sections of each tissue were analyzed for GFP and DAPI staining by confocal microscopy. Original magnification, $\times 400$. **(B)** Equivalent delivery of adenovirus to the livers of each experimental group ($n = 5$). Following administration of 50 mg/kg GW3965 to Ad-shCon or Ad-shTRAP80 injected mice, the livers were harvested and the mRNA levels of GFP were determined by qRT-PCR. Data are presented as the mean \pm SEM.

Supplemental Figure 6




Supplemental Figure 6. Knockdown of hepatic TRAP80 ameliorates T0901317-induced fatty liver and the aberrant serum lipid profile. (A) Knockdown of hepatic TRAP80 by tail vein injection of Ad-shTRAP80. After Ad-shTRAP80 injection, the livers were harvested and the protein levels of TRAP80 were determined by immunoblot analysis. Relative band intensities were calculated by Image J. (B) Representative images of hematoxylin and eosin (H&E) and oil Red O-stained liver of Ad-shTRAP80 injected mice following the administration of 50 mg/kg T0901317 for 3 days. Original magnification, $\times 200$. (C–G) Changes in the hepatic triglyceride and serum lipid profile in mice injected with Ad-shTRAP80 via the tail vein (shCon+vehicle, $n = 5$; shCon+T1317, $n = 8$; shTRAP80+vehicle, $n = 5$; shTRAP80+T1317, $n = 9$). Data are presented as the mean \pm SEM. TG, triglyceride. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, one-way ANOVA.

Supplemental Figure 7



Supplemental Figure 7. Effects of GW3965 on serum lipoprotein profiles in Ad-shTRAP80 infected ApoE^{-/-} mice. Ad-shCon or Ad-shTRAP80 infected ApoE^{-/-} mice were administered with 50 mg/kg GW3965 for 3 days. Lipoproteins were separated from pooled mouse serum by FPLC ($n = 5$). The concentration of cholesterol (A) or triglyceride (B) in each eluted fraction was determined enzymatically.

Supplemental Figure 8



Supplemental Figure 8. Effects of TRAP80 on T0901317-dependent expression of metabolic genes in the liver. The effects of TRAP80 knockdown on the transcript levels of lipogenesis- (A) or RCT-related genes (B) in the livers of mice treated with T0901317 (shCon+vehicle, $n = 5$; shCon+T1317, $n = 8$; shTRAP80+vehicle, $n = 5$; shTRAP80+T1317, $n = 9$). The mRNA levels were measured by qRT-PCR. Data are presented as the mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, one-way ANOVA.

Supplemental Table 1. Results of MALDI-TOF analysis of LXR α -interacting proteins.

Protein	Score ^A	Expect ^B	No. of peaks identified ^C	Masses matched ^D	Protein mass	Accession No.
TRAP230	134	6.2e-10	30	36.6%	247	Q93074
TRAP220	34	6.3	9	23.7%	168	Q15648
CRSP130	100	1.5e-6	18	33.3%	156.4	Q9ULK4
TRAP80	81	1.2e-4	16	19.3%	73	Q9NVC6

^A Protein score is a measure of the statistical significance of a match. A score greater than 65 is significant. ($p < 0.05$, default significance threshold)

^B Number of matches with equal or better scores expected to occur by chance alone. This is directly equivalent to the E-value in a BLAST search result. The lower the expectation value, the more significant the score.

^C Number of mass values matched.

^D Percentage of number of mass values matched in number of mass values searched

Supplemental Table 2. List of primers used for cloning.

Cloning Oligo Name	Sequence (5'→3')^A
mSREBP-1c (-550/+42) For	CGGGGTACCCCCCCTCCTTGAACAA
mSREBP-1c (-550/+42) Rev	CCGCTCGAGCCTAGGGCGTGCAGACGC
mSREBP-1c (mt LXRE a) For	ACGACAGAGT <u>CCGCCAGAAT</u> CCCCAGC
mSREBP-1c (mt LXRE a) Rev	GCTGGGG <u>ATTCTGGCGGACT</u> CTGTCTGT
mSREBP-1c (mt LXRE b) For	AAGCGGAAG <u>TCCGCTAGAAAT</u> CCCCGGC
mSREBP-1c (mt LXRE b) Rev	GCCGGGG <u>ATTCTAGCGGACT</u> TCCGCCTT
hABCA1 (-928/+101) For	CGGGGTACCTAAGTTGGAGGTCTGGAG
hABCA1 (-928/+101) Rev	CCGCTCGAGGCTCTGTTGGTGC
hABCA1 (mt LXRE) For	AGGCTTTGTGTGATAGTA <u>ACTGCTGCGCT</u>
hABCA1 (mt LXRE) Rev	AGCGCAG <u>CAGTTACTATCACACAAAGCCT</u>
Ad-shTRAP80 (1587) For	CGCGTCAGAGATGGTCGGGTAATCATTGATATCCGTGATTACCCGACCATCT CTTTTTTCCAAA
Ad-shTRAP80 (1587) Rev	AGCTTTTGAAAAAAGAGATGGTCGGGTAATCACGGATATCAATGATTACCC GACCATCTCTGA

^A Mutated nucleotides are underlined.

Supplemental Table 3. List of primers used for ChIP.

ChIP Oligo Name	Sequence (5'→3')	Notes
mSREBP-1c (LXRE) For	AGGCTCTTTTCGGGGATGG	
mSREBP-1c (LXRE) Rev	TGGGGTTACTGGCGGTAC	
mABCA1 (LXRE) For	GGGGAAAGAGGGAGAGAACAG	
mABCA1 (LXRE) Rev	GAATTACTGGTTTTTGCCGC	
mSREBP-1c (Exon) For	TTTGTCATTGGCTGTGGTCTTC	Non-LXRE
mSREBP-1c (Exon) Rev	CGGCATGGTCCTGATTGC	Non-LXRE
mABCA1 (Exon) For	GGCAGTGCCTTTGTAGCCTATG	Non-LXRE
mABCA1 (Exon) Rev	GGTCCACACCAGAGTTTCACA	Non-LXRE

Supplemental Table 4. List of primers used for gene expression analysis by qRT-PCR.

Gene name	Forward primer sequences	Reverse primer sequences
hTRAP80	CCTTCCGAGTAGCTGGGACC	AAATTAGCCAGGCGTGGTTG
hSREBP-1c	CCATCTGTGAGAAGGCCAGTG	GGTGTGGTAGCCAGGCTGTC
hABCA1	GAGAAGCTTTCAACGAGACTAACCAG	TGAAGCGAGATATGGTCCGG
hRPS29	CGCGAAGGATATCGGTTTCA	GCCCCGGATAATCCTCTGA
mTRAP80	CCTTGGGACTCTGTGAGGAA	GTGGACTCTGTTTGGGAGGA
mLXR α	GCAGCTGGGCATGATCG	CTGTTACACTGTTGCTGGGCA
mLXR β	TACCTCCGCCACGTCACC	GGATCAGTCTCCTGCCCTC
mSREBP-1c	CAGCCATGGATTGCACATTTG	GTCTTGGTTGTTGATGAGCTGG
mFAS	CTGCAGCTGTCAGTGTGAAGAAG	GCAGCATTTTTACCAGGTTGGT
mSCD1	AGCTCAGTCTCACTCCTTCCCTTA	CAGCCAGCCTCTTGACTATTCC
mABCA1	GACCCGTA CTCTCGCAGGG	CCTTGCCGGTATTTTAGCAGG
mABCG1	TTCATCGTCCTGGGCATCTT	GAAATAGGCGATGAGCCGC
mABCG5	TCAATGAGTTTTACGGCCTGAA	GCACATCGGGTGATTTAGCA
mABCG8	CGGAGCACTGTGCCTACGT	CGCAGGTTTGTGAGCCAGTA
mIDOL	TGTGGAGCCTCATCTCATCTT	AGGGACTCTTTAATGTGCAAGAA
mCOX-2	AACCGCATTGCCTCTGAAT	CATGTTCCAGGAGGATGGAG
miNOS	CGAAACGCTTCACTTCCAA	TGAGCCTATATTGCTGTGGCT
mRPS29	CGCAAATACGGGCTGAACA	GCCTATGTCCTTCGCGTACTG